Evidence Table 76. KQ2—Continuous data—Diastolic blood pressure (DBP)

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ferraro 200922  parallel | Unclear | ramipril | 10 | Omega-3 (EPA, DHA, or both). | 15 | NR | Mean: 73.5  Median  SD: 20.3 | NR | NR |  | medium |
|  | No treatment (aside from CVD drug) | 15 | Mean:76.7  Median  SD: 9.0 | NR |
| Meyer 200746  parallel | Unclear | simvastatinstatin, 13 atorvastatin, 4 pravastatin, 2 cerivastatin and 2 ﬂuvastatin | 81 | Fish/marine oils. | 13 | Supine in clinic | NR | NR | NR | Report states that no changes were noted in DBP across groups and results are not shown | medium |
|  | Fish/marine oils. | 13 | NR | NR |
|  | Placebo | 14 |
| Sutken 200663  parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E. | 22 | NR | Mean: 84  Median  SD:  SE: 4  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | high |
|  | No treatment (aside from CVD drug) | 23 | Mean:80  Median  SD:  SE:6.4  Lower:  Upper: | Mean:  Median:  SD:  P: |

| Evidence Table 76. KQ2—Continuous data—Diastolic blood pressure (DBP) (continued) | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Sutken 200663  parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E. | 12 | NR | Mean: 80  Median  SD:  SE:3.9  Lower:  Upper: | NR | NR |  | high |
|  | No treatment (aside from CVD drug) | 10 | Mean:81  Median  SD:  SE:4.2  Lower:  Upper: | NR |
| Macan 200640  parallel | Low and/or Moderate | Warfarin | NR | Garlic. | 22 | NR | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-0.5  % mean:  Median:  SD: 11.8  P: | Mean:  Median:  SD:  P: 0.829 |  | medium |
|  | Placebo | 26 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:0.3  Median:  SD: 13.7  P: |
| Barbagallo 19995  parallel | Unclear | furosemide | 25 | Vitamin E. | 12 | overnight fast, supine at rest, empty bladder | Mean:82  Median  SD: 4  SE:  Lower:  Upper: | Mean:-8  % mean:  Median:  SD:  P:  <0.005 | Mean:  Median:  SD:  P: | calculation of mean change from baseline questionably as it won’t be useable (SD cannot be inferred, I don’t think.). | medium |
|  | No treatment (aside from CVD drug) | 12 | Mean:84  Median  SD: 6  SE:  Lower:  Upper: | Mean:-9  Median:  SD:  P:  <0.005 |
| Howe 199430  parallel | Unclear | Captopril | 61 | Fish/marine oils. | 14 | NR | Mean: 77  Median  SD:  SE:2  Lower:  Upper: | Mean:3.1  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | outcomes in this study are reported as the average of three measurment during the treatment peiod. | medium |
|  | Placebo | 14 | Mean:79  Median  SD:  SE:2  Lower:  Upper: | Mean:2.3  Median:  SD:  P: |
|  | Fish/marine oils. | 14 | Mean:79  Median  SD: 2  SE:  Lower:  Upper: | Mean:4.0  Median:  SD:  1.1  P: |
|  | Placebo | 14 | Mean:77  Median  SD: 2  SE:  Lower:  Upper: | Mean:4.4  Median:  SD:  1.7  P: |
| Paolisso 199257  parallel | Unclear | hydrochlorthiazide | 25 | Magnesium. | 9 | supine, fasted (12 h) and at rest for 30 minutes - measured over 60 minutes, mean of last 10 minutes of measurement included. | Mean: 95  Median  SD:  SE:3  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P:  <0.05 |  | medium |
|  | Placebo | 9 | Mean:89  Median  SD:  SE:5  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Nordøy 200355  parallel | Mod and high risk | atorvastatin | 10 | Fish/marine oils. | 22 | NR | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-2.8  % mean:  Median:  SD:  7.2  P:  <0.05 | Mean:  Median:  SD:  P:  0.92 |  | medium |
|  | Placebo | 20 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-3.0  Median:  SD:  8.1  P: |
| Reyes 198459  parallel | Low and/or Moderate | hydrochlorothiazide | 50 | Magnesium. | 13 | Supine diastolic | Mean: 104.4  Median  SD:  SE:3.9  Lower:  Upper: | Mean:-6  % mean:  Median:  SD:  P:  <0.05 | Mean:  Median:  SD:  P: | Data for % change measured from graph and verified with numerical data in abstract | medium |
|  | Placebo | 8 | Mean:1.5  Median  SD:  SE:4.2  Lower:  Upper: | Mean:  % mean: -3.4  Median:  SD:  P:  <0.05 |
| Reyes 198459  parallel | Low and/or Moderate | hydrochlorothiazide | 50 | Magnesium. | 13 | Erect diastolic blood pressure | Mean: 106  Median  SD:  SE:2  Lower:  Upper: | Mean:-5  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Data extracted from bar charts - method of extraction verified for other variables that had corresponding numerical summary. In this case for final mean and SEM 1.9 cm = 40 mmHg and results rounded to nearest whole mmHg. For % change from time of randomization 1.1 cm = 2.5% and results rounded to nearest 0.5% | medium |
| Placebo | 8 | Mean: 105  Median  SD:  SE:4  Lower:  Upper: | Mean:-3  % mean:  Median:  SD:  P: |
| Dehmer 198817  parallel | At high risk for CHD | aspirin + Dipyridamole + ca channel blockers) | ASA: 325; dipyridamole: 225; Ca blocker: NR | Omega-3 (EPA, DHA, or both). | 43 | NR | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | No treatment (aside from CVD drug) | 39 | Mean:36  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Wolf 200668  crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | NR | NR | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: | Study states that: Laboratory findings in all subjects were unremarkable and did not indicate any differences between the treatment groups. Similarly, no noteworthy changes of vital sign variables occurred during the study | low-medium |
|  |  | NR | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Paolisso 199556  crossover | At high risk for CHD | nifedipine | 88 | Vitamin E | 30 | NR | Mean: 85  Median  SD:  SE:0.7  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 30 | Mean:86  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Lungershausen 199438  crossover | Unclear | b-blockers | NR | Fish/marine oils | 25 | Clinical diastolic BP - Resting for 5 min, empty bladder, fasted and no exercise for 2 hours; average of 3 or 4 readings after discarding initial reading; measured using automated oscillometric monitor | Mean: 72.5  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P:  <0.05 | Data of mean measured from histogram (10 mmHg = 2.2 cm). Measure of dispersion not stated. This study is at risk of selective outcome reporting; p-values for crude difference also don't make sense in context of graph. I would approach this data with e | medium |
|  | Placebo | 25 | Mean:75.5  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Lungershausen 199438  crossover | Unclear | b-blockers | NR | Fish/marine oils | 25 | Ambulatory diastolic BP - Measured over next 24 hours using Spacelab 90207 instrument, same time of day; taken at 20 min intervals during wake and every 1 hour during sleep. | Mean: 76  Median  SD:  SE:  Lower:  Upper: | Mean:2.3  % mean:  Median:  SD:  0.8  P: | Mean:  Median:  SD:  P:  <0.01 | Data of mean measured from histogram (10 mmHg = 2.2 cm). Measure of dispersion not stated. Data of mean difference in text. This study is at risk of selective outcome reporting; p-values for crude difference also don't make sense in context of graph. | medium |
|  | Placebo | 25 | Mean:78  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  1  P: |
| Mueller 199151  crossover | Low and/or Moderate | aspirin | 325-single dose | Fish/marine oils | 12 | before and 90 minutes after a single oral 325-mg dose of aspirin. Done by blinded operator | Mean: 77.5  Median  SD: 11.7  SE:  Lower:  Upper: | Mean:-2  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 12 | Mean:74.08  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Maki 200841  crossover | Low and/or Moderate | simvastatin | 20 | Omega-3 | 39 | At rest, seated | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  % mean: -3.3  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 40 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |
| Wirell 199467  Crossover | Unclear | metoprolol, atenolol, pindolol & propanolol | NR | magnesium | 39 | standing | Mean: 100.84  Median  SD: 9.48 | NR | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 39 | Mean:102.49 | NR |
| Wirell 199467  Crossover | Unclear | metoprolol, atenolol, pindolol & propanolol | NR | magnesium | 39 | supine | Mean: 93.03  Median  SD: 9.37  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P: | NR |  | medium |
|  | Placebo | 39 | Mean:95.68 | NR |
|  |  |  | NR | NR |